Semaglutide and Physical Activity for Obesity and Multimorbidity

NCT06234111 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide, combined with increased physical activity, helps people with obesity and multiple health conditions to be more active in their daily lives.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Type Observational

Participants 35 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-02 · est. completion 2026-11

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT06234111 ↗

Description as written by the study sponsor.

The aim of this observational study is to explore and describe changes in cardiometabolic health, physical activity, physical capacity, and wellbeing during interdisciplinary Semaglutide-based weight loss treatment in patients with severe obesity and multimorbidity. This study is explorative and therefore does not include hypothesis testing.

Treatments tested

Semaglutide 2.4 mg, total diet replacement, behavioural intervention also known as Wegovy, Nupo, Dietary counseling Combination Product

Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.

Main thing measured	Habitual physical activity
Sponsor	Hvidovre University Hospital
Conditions studied	Obesity Morbid, Multimorbidity, Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06234111 ↗